← Leaderboards
Robert M Prins
University Of California Los Angeles
$8,963,397
Attributed
$10,346,483
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,346,483 · 13
By mechanism
R01$5,314,006 · 4
P50$3,598,161 · 6
K01$705,086 · 1
R21$380,205 · 1
T32$349,025 · 1
Top collaborators
- Yi Xing5 shared
- David Andrew Largaespada2 shared
- Benjamin M. Ellingson1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Antoni Ribas$28,929,216
- Linda M Liau$8,990,878
- Benjamin M. Ellingson$5,183,626
- David Sigmund Liebeskind$10,675,130
- James S. Economou$9,911,213
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteImmunotherapyTumorDesignBrainImmune ResponseBrain NeoplasmsCellsDendritic CellsGliomaNeoplastic CellInnovationBaseImmunePhysiologic PulseTranslational ResearchPreclinical StudyTumor ImmunityResponseVaccinationSamplingGlioblastomaImmunologicsClinical Trials
Grant awards (41)
Neoadjuvant checkpoint blockade for recurrent glioblastoma$493,424
R01 · FY2025 · CA · contact PI
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition$402,824
P50 · FY2025 · CA · contact PI
Neuro-Oncology Translational Research Training Program (NOTR-TP)$349,025
T32 · FY2025 · CA · contact PI
Developmental Research Program$125,708
P50 · FY2025 · CA · contact PI
Developmental Research Program$8,612
P50 · FY2025 · CA · contact PI
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition$8,612
P50 · FY2025 · CA · contact PI
Neoadjuvant checkpoint blockade for recurrent glioblastoma$468,752
R01 · FY2024 · CA · contact PI
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition$413,778
P50 · FY2024 · CA · contact PI
Developmental Research Program$129,127
P50 · FY2024 · CA · contact PI
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition$86,121
P50 · FY2024 · CA · contact PI
Neoadjuvant checkpoint blockade for recurrent glioblastoma$483,557
R01 · FY2023 · CA · contact PI
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy$402,460
R01 · FY2023 · CA · contact PI
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition$378,369
P50 · FY2023 · CA · contact PI
Developmental Research Program$118,075
P50 · FY2023 · CA · contact PI
Neoadjuvant checkpoint blockade for recurrent glioblastoma$509,375
R01 · FY2022 · CA · contact PI
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy$402,457
R01 · FY2022 · CA · contact PI
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition$372,200
P50 · FY2022 · CA · contact PI
Developmental Research Program$116,154
P50 · FY2022 · CA · contact PI
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy$410,675
R01 · FY2021 · CA · contact PI
Developmental Research Program$72,083
P50 · FY2021 · CA · contact PI
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy$410,675
R01 · FY2020 · CA · contact PI
Developmental Research Program$73,659
P50 · FY2020 · CA · contact PI
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy$410,675
R01 · FY2019 · CA · contact PI
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma$345,824
P50 · FY2019 · CA · contact PI
Developmental Research Program$72,084
P50 · FY2019 · CA · contact PI
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma$371,981
P50 · FY2018 · CA · contact PI
Developmental Research Program$77,537
P50 · FY2018 · CA · contact PI
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma$352,032
P50 · FY2017 · CA · contact PI
Developmental Research Program$73,381
P50 · FY2017 · CA · contact PI
Immunotherapeutic targeting of the Glioblastoma Mutanome$200,100
R21 · FY2016 · CA · contact PI
Immunotherapeutic targeting of the Glioblastoma Mutanome$180,105
R21 · FY2015 · CA · contact PI
Optimizing Induction Conditions for Immunotherapeutic CTL$382,596
R01 · FY2014 · CA · contact PI
CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists$234,840
R01 · FY2010 · CA · contact PI
Immune targeting of melanoma-associated antigens in glioma$148,770
K01 · FY2010 · CA · contact PI
CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists$234,840
R01 · FY2009 · CA · contact PI
Immune targeting of melanoma-associated antigens in glioma$148,770
K01 · FY2009 · CA · contact PI
CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists$234,840
R01 · FY2008 · CA · contact PI
Immune targeting of melanoma-associated antigens in glioma$148,770
K01 · FY2008 · CA · contact PI
CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists$234,840
R01 · FY2007 · CA · contact PI
Immune targeting of melanoma-associated antigens in glioma$141,462
K01 · FY2007 · CA · contact PI
Immune targeting of melanoma-associated antigens in glioma$117,314
K01 · FY2006 · CA · contact PI